Ziopharm Oncology (ZIOP) Posts Q1 Loss of 69c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ZIOPHARM Reports First-Quarter 2015 Financial Results and Recent Activities
May 7, 2015 4:41 PM EDTBOSTON, May 7, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced financial results for the first quarter ended March 31, 2015, and provided an update on the company's recent activities.
"Through new and existing partnerships with Intrexon and Merck Serono, ZIOPHARM now links a set of immunotherapy programs and technologies with transformative potential in the treatment of cancer," said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of ZIOPHARM. "Our goal in the coming quarters is to work with our partners to see that these technologies are rapidly integrated and that their promise... More
ZIOPHARM Reports First-Quarter 2015 Financial Results and Recent Activities
May 7, 2015 4:41 PM EDTBOSTON, May 7, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced financial results for the first quarter ended March 31, 2015, and provided an update on the company's recent activities.
"Through new and existing partnerships with Intrexon and Merck Serono, ZIOPHARM now links a set of immunotherapy programs and technologies with transformative potential in the treatment of cancer," said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of ZIOPHARM. "Our goal in the coming quarters is to work with our partners to see that these technologies are rapidly integrated and that their promise... More
